Trial Outcomes & Findings for A Clinical Study Investigating the Effects of a Dentifrice Containing 67% Sodium Bicarbonate When Used Twice Daily for 12 Weeks on Gingivitis Treatment and Plaque Removal (NCT NCT05654662)

NCT ID: NCT05654662

Last Updated: 2025-01-13

Results Overview

The number of bleeding sites was calculated using the bleeding index (BI) assessment. The BI was assessed for all evaluable surfaces (having two-thirds of the natural tooth surface gradable for the assessment) of the facial and lingual/palatal gingiva, 6 sites per tooth (mesiobuccal, buccal, and distobuccal; mesiolingual/palatal, lingual/palatal, and distolingual/palatal). Evaluable tooth sites were probed, and gingival bleeding was assessed for approximately 30 seconds after probing. The number of bleeding sites for each participant was calculated as the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Change from Baseline was calculated by subtracting the Baseline value from the value at Week 12. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival bleeding.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

197 participants

Primary outcome timeframe

Baseline and Week 12

Results posted on

2025-01-13

Participant Flow

This study was conducted at a single center in the United Kingdom.

A total of 204 participants were screened of which 197 participants were enrolled, and 190 participants were randomized to receive treatment in 2 groups: Test Product group (94 participants) and Reference Product group (96 participants). 14 participants were not randomized (9 participants did not meet study criteria; 2 participants were lost to follow-up; and 3 participants withdrew their consent). A total of 188 randomized participants completed the study.

Participant milestones

Participant milestones
Measure
Test Product (Corsodyl Original Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67 percent (%) weight/weight (w/w) Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Reference Product (Colgate Cavity Protection Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Overall Study
STARTED
94
96
Overall Study
COMPLETED
92
96
Overall Study
NOT COMPLETED
2
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Test Product (Corsodyl Original Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67 percent (%) weight/weight (w/w) Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Reference Product (Colgate Cavity Protection Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Overall Study
Withdrawal by Subject
1
0
Overall Study
A death in the family
1
0

Baseline Characteristics

A Clinical Study Investigating the Effects of a Dentifrice Containing 67% Sodium Bicarbonate When Used Twice Daily for 12 Weeks on Gingivitis Treatment and Plaque Removal

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Reference Product (Colgate Cavity Protection Toothpaste)
n=96 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Total
n=190 Participants
Total of all reporting groups
Age, Continuous
39.2 years
STANDARD_DEVIATION 12.08 • n=99 Participants
39.8 years
STANDARD_DEVIATION 13.20 • n=107 Participants
39.5 years
STANDARD_DEVIATION 12.63 • n=206 Participants
Sex: Female, Male
Female
69 Participants
n=99 Participants
67 Participants
n=107 Participants
136 Participants
n=206 Participants
Sex: Female, Male
Male
25 Participants
n=99 Participants
29 Participants
n=107 Participants
54 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
94 Participants
n=99 Participants
96 Participants
n=107 Participants
190 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race/Ethnicity, Customized
African American/African Heritage
4 Participants
n=99 Participants
8 Participants
n=107 Participants
12 Participants
n=206 Participants
Race/Ethnicity, Customized
Asian - Central/South Asian Heritage
5 Participants
n=99 Participants
10 Participants
n=107 Participants
15 Participants
n=206 Participants
Race/Ethnicity, Customized
Asian - East Asian Heritage
1 Participants
n=99 Participants
2 Participants
n=107 Participants
3 Participants
n=206 Participants
Race/Ethnicity, Customized
Asian - South East Asian Heritage
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
Race/Ethnicity, Customized
White - White/Caucasian/European Heritage
73 Participants
n=99 Participants
71 Participants
n=107 Participants
144 Participants
n=206 Participants
Race/Ethnicity, Customized
Multiple
10 Participants
n=99 Participants
5 Participants
n=107 Participants
15 Participants
n=206 Participants

PRIMARY outcome

Timeframe: Baseline and Week 12

Population: mITT Population. Here, overall number analyzed is defined as the number of participants with data available for analysis of this outcome measure.

The number of bleeding sites was calculated using the bleeding index (BI) assessment. The BI was assessed for all evaluable surfaces (having two-thirds of the natural tooth surface gradable for the assessment) of the facial and lingual/palatal gingiva, 6 sites per tooth (mesiobuccal, buccal, and distobuccal; mesiolingual/palatal, lingual/palatal, and distolingual/palatal). Evaluable tooth sites were probed, and gingival bleeding was assessed for approximately 30 seconds after probing. The number of bleeding sites for each participant was calculated as the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Change from Baseline was calculated by subtracting the Baseline value from the value at Week 12. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival bleeding.

Outcome measures

Outcome measures
Measure
Test Product (Corsodyl Original Toothpaste)
n=92 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Reference Product (Colgate Cavity Protection Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Adjusted Mean Change From Baseline in Number of Bleeding Sites at Week 12
-4.3 bleeding sites
Standard Error 1.44

SECONDARY outcome

Timeframe: Baseline and Week 12

Population: mITT Population. Here, overall number analyzed is defined as the number of participants with data available for analysis of this outcome measure.

The number of bleeding sites was calculated using the BI assessment. The BI was assessed for all evaluable surfaces (having two-thirds of the natural tooth surface gradable for the assessment) of the facial and lingual/palatal gingiva, 6 sites per tooth (mesiobuccal, buccal, and distobuccal; mesiolingual/palatal, lingual/palatal, and distolingual/palatal). Evaluable tooth sites were probed, and gingival bleeding was assessed for approximately 30 seconds after probing. The number of bleeding sites for each participant was calculated as the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Change from Baseline was calculated by subtracting the Baseline value from the value at Week 12. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival bleeding.

Outcome measures

Outcome measures
Measure
Test Product (Corsodyl Original Toothpaste)
n=92 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Reference Product (Colgate Cavity Protection Toothpaste)
n=96 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Adjusted Mean Change From Baseline in Number of Bleeding Sites at Week 12 (Test Product Versus [vs.] Reference Product)
-4.3 bleeding sites
Standard Error 1.44
2.3 bleeding sites
Standard Error 1.42

SECONDARY outcome

Timeframe: Baseline, Week 3, and Week 6

Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.

The number of bleeding sites was calculated using the BI assessment. The BI was assessed for all evaluable surfaces (having two-thirds of the natural tooth surface gradable for the assessment) of the facial and lingual/palatal gingiva, 6 sites per tooth (mesiobuccal, buccal, and distobuccal; mesiolingual/palatal, lingual/palatal, and distolingual/palatal). Evaluable tooth sites were probed, and gingival bleeding was assessed for approximately 30 seconds after probing. The number of bleeding sites for each participant was calculated as the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Change from Baseline was calculated by subtracting the Baseline value from the value at each indicated timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival bleeding.

Outcome measures

Outcome measures
Measure
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Reference Product (Colgate Cavity Protection Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Adjusted Mean Change From Baseline in Number of Bleeding Sites at Week 3 and Week 6
Change from Baseline at Week 3
-2.4 bleeding sites
Standard Error 1.02
Adjusted Mean Change From Baseline in Number of Bleeding Sites at Week 3 and Week 6
Change from Baseline at Week 6
-2.4 bleeding sites
Standard Error 1.26

SECONDARY outcome

Timeframe: Baseline, Week 3, and Week 6

Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.

The number of bleeding sites was calculated using the BI assessment. The BI was assessed for all evaluable surfaces (having two-thirds of the natural tooth surface gradable for the assessment) of the facial and lingual/palatal gingiva, 6 sites per tooth (mesiobuccal, buccal, and distobuccal; mesiolingual/palatal, lingual/palatal, and distolingual/palatal). Evaluable tooth sites were probed, and gingival bleeding was assessed for approximately 30 seconds after probing. The number of bleeding sites for each participant was calculated as the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Change from Baseline was calculated by subtracting the Baseline value from the value at each indicated timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival bleeding.

Outcome measures

Outcome measures
Measure
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Reference Product (Colgate Cavity Protection Toothpaste)
n=96 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Adjusted Mean Change From Baseline in Number of Bleeding Sites at Week 3 and Week 6 (Test Product vs. Reference Product)
Change from Baseline at Week 3
-2.4 bleeding sites
Standard Error 1.02
1.4 bleeding sites
Standard Error 1.02
Adjusted Mean Change From Baseline in Number of Bleeding Sites at Week 3 and Week 6 (Test Product vs. Reference Product)
Change from Baseline at Week 6
-2.4 bleeding sites
Standard Error 1.26
2.9 bleeding sites
Standard Error 1.25

SECONDARY outcome

Timeframe: Baseline, Weeks 3, 6 and 12

Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.

The BI was assessed for all evaluable surfaces (having two-thirds of the natural tooth surface gradable for the assessment) of the facial and lingual/palatal gingiva, 6 sites per tooth (mesiobuccal, buccal, and distobuccal; mesiolingual/palatal, lingual/palatal, and distolingual/palatal). Evaluable tooth sites were probed, and gingival bleeding was assessed for approximately 30 seconds after probing and scored on a 3-point scale ranging from 0 to 2, where 0=No bleeding after 30 seconds; 1=Bleeding observed within 30 seconds of probing; 2=Bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated better outcome. Change from Baseline was calculated by subtracting the Baseline value from the value at each indicated timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival bleeding.

Outcome measures

Outcome measures
Measure
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Reference Product (Colgate Cavity Protection Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Adjusted Mean Change From Baseline in Mean BI at Weeks 3, 6 and 12
Change from Baseline at Week 3
-0.04 score on a scale
Standard Error 0.008
Adjusted Mean Change From Baseline in Mean BI at Weeks 3, 6 and 12
Change from Baseline at Week 6
-0.04 score on a scale
Standard Error 0.009
Adjusted Mean Change From Baseline in Mean BI at Weeks 3, 6 and 12
Change from Baseline at Week 12
-0.06 score on a scale
Standard Error 0.011

SECONDARY outcome

Timeframe: Baseline, Weeks 3, 6 and 12

Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.

The BI was assessed for all evaluable surfaces (having two-thirds of the natural tooth surface gradable for the assessment) of the facial and lingual/palatal gingiva, 6 sites per tooth (mesiobuccal, buccal, and distobuccal; mesiolingual/palatal, lingual/palatal, and distolingual/palatal). Evaluable tooth sites were probed, and gingival bleeding was assessed for approximately 30 seconds after probing and scored on a 3-point scale ranging from 0 to 2, where 0=No bleeding after 30 seconds; 1=Bleeding observed within 30 seconds of probing; 2=Bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated better outcome. Change from Baseline was calculated by subtracting the Baseline value from the value at each indicated timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival bleeding.

Outcome measures

Outcome measures
Measure
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Reference Product (Colgate Cavity Protection Toothpaste)
n=96 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Adjusted Mean Change From Baseline in Mean BI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 12
-0.06 score on a scale
Standard Error 0.011
-0.01 score on a scale
Standard Error 0.011
Adjusted Mean Change From Baseline in Mean BI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 3
-0.04 score on a scale
Standard Error 0.008
-0.01 score on a scale
Standard Error 0.008
Adjusted Mean Change From Baseline in Mean BI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 6
-0.04 score on a scale
Standard Error 0.009
-0.00 score on a scale
Standard Error 0.009

SECONDARY outcome

Timeframe: Baseline, Weeks 3, 6 and 12

Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.

MGI assessment is a non-invasive evaluation which focuses on visual symptoms of gingivitis (example, redness, texture, edema). MGI was assessed for all evaluable surfaces of facial and lingual/palatal gingiva,4 sites per tooth and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation;1=Mild inflammation;slight change in color,little change in color;little change in texture of any portion of marginal or papillary gingival unit;2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit;3=Moderate inflammation;glazing, redness, edema, and/or hypertrophy of marginal or papillary gingival unit;4= Severe inflammation;marked redness, edema and/or hypertrophy of marginal or papillary gingival unit,spontaneous bleeding, congestion, or ulceration. Lower score indicated better outcome. Change from Baseline=Value at each indicated timepoint minus Baseline \[Day 0\] value. A negative change from Baseline indicated improvement in symptoms.

Outcome measures

Outcome measures
Measure
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Reference Product (Colgate Cavity Protection Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Adjusted Mean Change From Baseline in Mean Mean Modified Gingival Index (MGI) at Weeks 3, 6 and 12
Change from Baseline at Week 3
-0.12 score on a scale
Standard Error 0.014
Adjusted Mean Change From Baseline in Mean Mean Modified Gingival Index (MGI) at Weeks 3, 6 and 12
Change from Baseline at Week 6
-0.19 score on a scale
Standard Error 0.019
Adjusted Mean Change From Baseline in Mean Mean Modified Gingival Index (MGI) at Weeks 3, 6 and 12
Change from Baseline at Week 12
-0.24 score on a scale
Standard Error 0.021

SECONDARY outcome

Timeframe: Baseline, Weeks 3, 6 and 12

Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.

MGI assessment is a non-invasive evaluation which focuses on visual symptoms of gingivitis (example, redness, texture, edema). MGI was assessed for all evaluable surfaces of facial and lingual/palatal gingiva,4 sites per tooth and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation;1=Mild inflammation;slight change in color,little change in color;little change in texture of any portion of marginal or papillary gingival unit;2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit;3=Moderate inflammation;glazing, redness, edema, and/or hypertrophy of marginal or papillary gingival unit;4= Severe inflammation;marked redness, edema and/or hypertrophy of marginal or papillary gingival unit,spontaneous bleeding, congestion, or ulceration. Lower score indicated better outcome. Change from Baseline=Value at each indicated timepoint minus Baseline \[Day 0\] value. A negative change from Baseline indicated improvement in symptoms.

Outcome measures

Outcome measures
Measure
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Reference Product (Colgate Cavity Protection Toothpaste)
n=96 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Adjusted Mean Change From Baseline in Mean MGI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 3
-0.12 score on a scale
Standard Error 0.014
-0.04 score on a scale
Standard Error 0.014
Adjusted Mean Change From Baseline in Mean MGI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 6
-0.19 score on a scale
Standard Error 0.019
-0.06 score on a scale
Standard Error 0.019
Adjusted Mean Change From Baseline in Mean MGI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 12
-0.24 score on a scale
Standard Error 0.021
-0.10 score on a scale
Standard Error 0.021

SECONDARY outcome

Timeframe: Baseline, Weeks 3, 6 and 12

Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.

TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (7-7 in each arch). 3 scores were recorded facially(distal, body, mesial sites), and 3 scores were recorded lingually(distal, body, mesial sites). Plaque was first disclosed using a dye solution and scored on a 6-point scale ranging from 0 to 5, where 0=No plaque; 1=Separate flecks of plaque at the cervical margin; 2=Thin continuous band of plaque (up to 1 millimeter\[mm\]) at the cervical margin; 3=Band of plaque wider than 1 mm but covering less than (\<)1/3 of the tooth surface; 4=Plaque covering greater than or equal to (\>=)1/3 but \<2/3 of the tooth surface; 5=Plaque covering \>=2/3 of the tooth surface. Mean overall TPI score=Average of TPI values over all tooth sites assessed for a participant. Lower score=better outcome. Change from Baseline=Value at each indicated timepoint minus Baseline value. Baseline=Day 0. A negative change from Baseline indicated improvement (less plaque accumulation).

Outcome measures

Outcome measures
Measure
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Reference Product (Colgate Cavity Protection Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Adjusted Mean Change From Baseline in Mean Overall TPI (Turesky Plaque Index) at Weeks 3, 6 and 12
Change from Baseline at Week 3
-0.32 score on a scale
Standard Error 0.033
Adjusted Mean Change From Baseline in Mean Overall TPI (Turesky Plaque Index) at Weeks 3, 6 and 12
Change from Baseline at Week 6
-0.31 score on a scale
Standard Error 0.043
Adjusted Mean Change From Baseline in Mean Overall TPI (Turesky Plaque Index) at Weeks 3, 6 and 12
Change from Baseline at Week 12
-0.41 score on a scale
Standard Error 0.047

SECONDARY outcome

Timeframe: Baseline, Weeks 3, 6 and 12

Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.

TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (7-7 in each arch). 3 scores were recorded facially (distal, body, mesial sites), and 3 scores were recorded lingually (distal, body, mesial sites). Plaque was first disclosed using a dye solution and scored on a 6-point scale ranging from 0 to 5, where 0=No plaque; 1=Separate flecks of plaque at the cervical margin; 2=Thin continuous band of plaque (up to 1 mm) at the cervical margin; 3=Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface; 4=Plaque covering \>=1/3 but \<2/3 of the tooth surface; 5=Plaque covering \>=2/3 of the tooth surface. Mean overall TPI score=Average of TPI values over all tooth sites assessed for a participant. Lower score=better outcome. Change from Baseline=Value at each indicated timepoint minus Baseline value. Baseline=Day 0. A negative change from Baseline indicated improvement (less plaque accumulation).

Outcome measures

Outcome measures
Measure
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Reference Product (Colgate Cavity Protection Toothpaste)
n=96 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Adjusted Mean Change From Baseline in Mean Overall TPI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 3
-0.32 score on a scale
Standard Error 0.033
-0.17 score on a scale
Standard Error 0.033
Adjusted Mean Change From Baseline in Mean Overall TPI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 6
-0.31 score on a scale
Standard Error 0.043
-0.14 score on a scale
Standard Error 0.043
Adjusted Mean Change From Baseline in Mean Overall TPI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 12
-0.41 score on a scale
Standard Error 0.047
-0.12 score on a scale
Standard Error 0.046

SECONDARY outcome

Timeframe: Baseline, Weeks 3, 6 and 12

Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.

TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (7-7 in each arch). 3 scores were recorded facially (distal, mesial sites), and 3 scores were recorded lingually (distal, mesial sites). Plaque was first disclosed using a dye solution and scored on a 6-point scale ranging from 0 to 5, where 0=No plaque; 1=Separate flecks of plaque at the cervical margin; 2=Thin continuous band of plaque (up to 1 mm) at the cervical margin; 3=Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface; 4=Plaque covering \>=1/3 but \<2/3 of the tooth surface; 5=Plaque covering \>=2/3 of the tooth surface. Mean interproximal TPI score=Average of TPI values over distal and mesial tooth sites assessed for a participant. Lower score indicated better outcome. Change from Baseline=Value at each indicated timepoint minus Baseline value. Baseline=Day 0. A negative change from Baseline indicated improvement (less plaque accumulation).

Outcome measures

Outcome measures
Measure
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Reference Product (Colgate Cavity Protection Toothpaste)
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Adjusted Mean Change From Baseline in Mean Interproximal TPI at Weeks 3, 6 and 12
Change from Baseline at Week 6
-0.34 score on a scale
Standard Error 0.047
Adjusted Mean Change From Baseline in Mean Interproximal TPI at Weeks 3, 6 and 12
Change from Baseline at Week 3
-0.35 score on a scale
Standard Error 0.036
Adjusted Mean Change From Baseline in Mean Interproximal TPI at Weeks 3, 6 and 12
Change from Baseline at Week 12
-0.42 score on a scale
Standard Error 0.052

SECONDARY outcome

Timeframe: Baseline, Weeks 3, 6 and 12

Population: mITT Population. Only those participants available at the indicated timepoints were analyzed.

TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (7-7 in each arch). 3 scores were recorded facially (distal, mesial sites), and 3 scores were recorded lingually (distal, mesial sites). Plaque was first disclosed using a dye solution and scored on a 6-point scale ranging from 0 to 5, where 0=No plaque; 1=Separate flecks of plaque at the cervical margin; 2=Thin continuous band of plaque (up to 1 mm) at the cervical margin; 3=Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface; 4=Plaque covering \>=1/3 but \<2/3 of the tooth surface; 5=Plaque covering \>=2/3 of the tooth surface. Mean interproximal TPI score=Average of TPI values over distal and mesial tooth sites assessed for a participant. Lower score indicated better outcome. Change from Baseline=Value at each indicated timepoint minus Baseline value. Baseline=Day 0. A negative change from Baseline indicated improvement (less plaque accumulation).

Outcome measures

Outcome measures
Measure
Test Product (Corsodyl Original Toothpaste)
n=94 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Reference Product (Colgate Cavity Protection Toothpaste)
n=96 Participants
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Adjusted Mean Change From Baseline in Mean Interproximal TPI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 3
-0.35 score on a scale
Standard Error 0.036
-0.19 score on a scale
Standard Error 0.036
Adjusted Mean Change From Baseline in Mean Interproximal TPI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 6
-0.34 score on a scale
Standard Error 0.047
-0.17 score on a scale
Standard Error 0.047
Adjusted Mean Change From Baseline in Mean Interproximal TPI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
Change from Baseline at Week 12
-0.42 score on a scale
Standard Error 0.052
-0.12 score on a scale
Standard Error 0.052

Adverse Events

Test Product (Corsodyl Original Toothpaste)

Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths

Reference Product (Colgate Cavity Protection Toothpaste)

Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Test Product (Corsodyl Original Toothpaste)
n=94 participants at risk
Participants were instructed to dose the toothbrush provided with full ribbon of test product (Corsodyl Original Toothpaste) containing 67% w/w Sodium Bicarbonate and 0.310% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Reference Product (Colgate Cavity Protection Toothpaste)
n=96 participants at risk
Participants were instructed to dose the toothbrush provided with full ribbon of reference product (Colgate Cavity Protection Toothpaste) containing 0.76% w/w Sodium Monofluorophosphate and 0.1% w/w Sodium Fluoride and brush their teeth for at least a minute, twice daily (morning and evening) for 12 weeks.
Gastrointestinal disorders
GINGIVAL BLEEDING
0.00%
0/94 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.
1.0%
1/96 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.
Gastrointestinal disorders
TOOTHACHE
0.00%
0/94 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.
1.0%
1/96 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.
Gastrointestinal disorders
VOMITING
0.00%
0/94 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.
1.0%
1/96 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.
Injury, poisoning and procedural complications
GINGIVAL INJURY
2.1%
2/94 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.
0.00%
0/96 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.
Nervous system disorders
MIGRAINE
0.00%
0/94 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.
1.0%
1/96 • From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days)
An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of one of the study products including any washout or lead-in product (or medical device), whether or not considered related to the study product, including any washout or lead-in product (or medical device). A Serious Adverse Event (SAE) was a particular category of an AE where the adverse outcome is serious.

Additional Information

Haleon Response Center

HALEON

Phone: +441932959500

Results disclosure agreements

  • Principal investigator is a sponsor employee HALEON agreements may vary with individual investigators but will not prohibit any investigator from publishing. HALEON supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
  • Publication restrictions are in place

Restriction type: OTHER